Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors.

Cancer gene therapy - 1 Jun 2000

Todo T, Rabkin S D, Martuza R L

Abstract excerpt

G207 is a multimutated, conditionally replicating herpes simplex virus type 1 (HSV-1) that retains an intact viral thymidine kinase (HSV-tk) gene. The virus exhibits oncolytic activity in various tumors and is being evaluated in patients with recurrent malignant glioma. In view of the potential for ganciclovir (GCV) to either enhance or inhibit the antitumoral activity of HSV-tk-retaining HSV-1 vectors, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Combined Modality Therapy
Share to Cytopathogenic Effect, Viral

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Ganciclovir

Share to Herpesvirus 1, Human

Share to Injections, Intraperitoneal

Share to Neuroblastoma

Share to Skin Neoplasms

Share to Survival Analysis

Source

Identifiers

PMID: 10880026
DOI: 10.1038/sj.cgt.7700182

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors.PMID 10880026Read ↗

Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice.Semantic proximity Read ↗

Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1.Semantic proximity Read ↗

Oncolytic virus therapy using genetically engineered herpes simplex virusesSemantic proximity Read ↗

Immuno-viral therapy as a new approach for the treatment of brain tumors.Semantic proximity Read ↗

Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus.Semantic proximity Read ↗

Phase Ib Trial of Mutant Herpes Simplex Virus G207 Inoculated Pre-and Post-tumor Resection for Recurrent GBMSemantic proximity Read ↗

Therapeutic efficacy of G207 in a novel peripheral nerve sheath tumor model.Semantic proximity Read ↗

Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation.Semantic proximity Read ↗

Multimutated herpes simplex virus g207 is a potent inhibitor of angiogenesis.Semantic proximity Read ↗

A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors.Semantic proximity Read ↗

Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.Semantic proximity Read ↗

Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.